Nov, 20 2017 15:50 JST

Source: Eisai

Eisai Receives IT Business Award for Medication Administration Support Device e-OKUSURI-SAN

Equipped with Functions to Support Looking After Patients

TOKYO, Nov, 20 2017 - (JCN Newswire) - Eisai Co., Ltd. has announced that it received an "IT Business Award" for its medication administration support device e-OKUSURI-SAN at the fiscal 2017 (35th) IT Awards held by the Japan Institute of Information Technology (JiIT).
Front of e-OKUSURI-SAN

The IT Awards are given to companies, organizations, other bodies and individuals in recognition of results from notable efforts made in "business innovation through high-level use of IT" by the JiIT, whose designated aim is to promote improvements in productivity in the activities of Japanese industry and government bodies as well as implementation of effective management systems. The "IT Business Award" received by Eisai was awarded based on the verification of notable results in realizing a strategic advantage as well as contributing to management via expansion and creation of business through the effective implementation and use of IT in business activities.

e-OKUSURI-SAN supports treatment administration for patients, families, pharmacists, nurses and caregivers, by ensuring that the prescribed dosage of medicine is administered at the scheduled time, thus helping to prevent patients from forgetting to take medicine or overdosing. The device is also equipped with a function to support looking after patients by allowing those concerned, including family and pharmacists, to remotely confirm a patient's record of medicine administration via an exclusive cloud website system.

In the demonstration experiments conducted ahead of the launch of e-OKUSURI-SAN as well as hearings post-launch, various benefits were observed, including an increase in administration rates, contribution to prevention of overdosing, a reduction in the burden on families, pharmacists, nurses and caregivers to support patients, and an enhancement in interprofessional collaboration through the provision of administration information.

In the selection for this award, the results of the new value provided by e-OKUSURI-SAN to home care patients as well as families and medical and nursing care professionals supporting the rehabilitation activities of patients were assessed, and selected for the "IT Business Award."

Eisai has been engaged for many years in activities for "creating communities where people can live with peace of mind." In carrying out these activities, Eisai has identified real world needs and issues. By providing solutions to these needs and issues in cooperation with stakeholders including local governments, medical institutions and pharmacies, Eisai seeks to make continued contributions to address the diverse needs of, as well as increasing the benefits provided to, patients and their families.


Up to four doses can be scheduled per day (morning, middle of the day, night, before bed), with a week's worth of medicine able to be set in the device. At the scheduled time, a tray with a medicine case slides out, with simultaneous audio and visual prompts. If the case has not been taken from the tray, the snooze function can be used to replay the audio prompts. If 40 minutes have passed without the medicine case being taken from the tray, the medicine case will be automatically retracted into the device. As a general rule, medicine cases cannot be retrieved until the next scheduled administration time to prevent patients from overdosing. Information on medicine administration is encrypted and managed individually on an exclusive website on the cloud. It is possible to have an email sent to registered individuals such as family members or pharmacists whenever a medicine case has been taken or if a medicine case was retracted without being taken.

Monthly data can be viewed as a line graph or table, making it easy to see if a patient is regularly following administration times or not. Eisai Co., Ltd. markets e-OKUSURI-SAN in Japan mainly through pharmacies, medical institutions and care facilities. For inquiries relating to the device, please visit: (available in Japanese only)

* e-OKUSURI-SAN is not a medical device.

About the Japan Institute of Information Technology

The Japan Institute of Information Technology (JiIT) was established in 1981 as an "organ for the promotion of management innovation through the utilization of IT." Conducting survey research and development into the digitalization of companies and encouraging the spread and implementation of the results, the JiIT aims to contribute the healthy development of Japanese society, economy and industry. Working to select themes in accordance with the needs of the times and expand its activities, the JiIT is pushing forward with the sound digitalization of both industries and companies.

About Eisai
Eisai Co., Ltd. is a leading global research and development-based pharmaceutical company headquartered in Japan. We define our corporate mission as "giving first thought to patients and their families and to increasing the benefits health care provides," which we call our human health care philosophy. With approximately 10,000 employees working across our global network of R&D facilities, manufacturing sites and marketing subsidiaries, we strive to realize our human health care philosophy by delivering innovative products in various therapeutic areas with high unmet medical needs, including Oncology and Neurology.

As a global pharmaceutical company, our mission extends to patients around the world through our investment and participation in partnership-based initiatives to improve access to medicines in developing and emerging countries.

For more information about Eisai Co., Ltd., please visit

Public Relations Department,
Eisai Co., Ltd.
Source: Eisai
Sectors: BioTech

Copyright ©2018 JCN Newswire. All rights reserved. A division of Japan Corporate News Network.


Front of e-OKUSURI-SAN

Related Press Release

Eisai and MSD Japan Commence Collaboration on Commercialization Activities for LENVIMA (Lenvatinib) in Japan
October 22 2018 16:34 JST
Eisai: Discovery of Candidate Compound as Potential Treatment for Parkinson's Disease Using iPS Cells
October 19 2018 11:18 JST
Eisai to Present Latest Data on Alzheimer's Disease / Dementia Pipeline at 11th Clinical Trials on Alzheimer's Disease Conference
October 18 2018 08:03 JST
Eisai and Purdue Pharma Announce Positive Topline Results of SUNRISE 2, the Second Phase 3 Pivotal Study of Lemborexant
October 17 2018 08:51 JST
Eisai Signs Collaboration Agreement for Anti-Obesity Agent Lorcaserin in Latin America With Eurofarma
October 16 2018 17:38 JST
Eisai's New Drug Application for Perampanel for Adjunctive Treatment of Partial Onset Seizures Accepted in China
October 12 2018 13:48 JST
Eisai to Present Abstracts on Oncology Products and Pipeline at ESMO 2018 Congress
October 10 2018 14:35 JST
New Data on Effect of Anti-Obesity Agent BELVIQ on Prevention and Remission of Type 2 Diabetes Presented at The European Association for the Study of Diabetes and Published in The Lancet
October 05 2018 09:30 JST
Eisai's Fycompa Newly Approved by U.S. FDA as Treatment for Partial-Onset Seizures in Pediatric Patients with Epilepsy
October 01 2018 07:48 JST
Eisai And Merck & Co. Announce China NMPA Approval of First Approval for LENVIMA (Lenvatinib) for Treatment of Unresectable HCC
September 05 2018 14:28 JST
More Press release >>

Latest Press Release

More Latest Release >>